The DESTINY-Breast, ASCENT, and TROPION trials enrolled distinct patient populations understudied with respect to the application of ADCs in the clinical setting—HER2-positive, triple-negative, and HR+/HER2− breast cancers, respectively. This evidence concerns the gene ERBB2 and breast carcinoma.